Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
144 hedge funds and large institutions have $1.23B invested in Revance Therapeutics, Inc. in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 64 increasing their positions, 33 reducing their positions, and 13 closing their positions.
400% more call options, than puts
Call options by funds: $5.45M | Put options by funds: $1.09M
108% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 13
94% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 33
69% more capital invested
Capital invested by funds: $732M → $1.23B (+$502M)
11% more funds holding
Funds holding: 130 → 144 (+14)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$24.9M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$21.5M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$11.5M |
| 4 |
BlackRock
New York
|
+$8.52M |
| 5 |
Jennison Associates
New York
|
+$8.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$36.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$17M |
| 3 |
Renaissance Technologies
New York
|
-$7M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$4.43M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$4.16M |
RVNC Hedge Fund Activity: Q2 2020 in Review
144 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2020, worth a combined $1.23B — up 69% from $732M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new RVNC positions and 13 closed out — a net gain of 14 holders — while 64 added to existing stakes and 33 trimmed.
The largest buyer was Polar Capital, adding an estimated $24.9M. The largest seller was Wellington Management Group, cutting an estimated $36.9M.
- 144 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2020, up from 130 in Q1 2020.
- Funds reported $1.23B of Revance Therapeutics, Inc. stock for Q2 2020, up 69% quarter-over-quarter.
- 27 funds opened new Revance Therapeutics, Inc. positions in Q2 2020 and 13 closed out, a net change of +14 holders.
- The largest Revance Therapeutics, Inc. buyer in Q2 2020 was Polar Capital, an estimated $24.9M added.
- The largest Revance Therapeutics, Inc. seller in Q2 2020 was Wellington Management Group, an estimated $36.9M sold.
Based on aggregated 13F filings for Q2 2020.